Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Predicting an accurate tamoxifen dose in hormone-positive breast cancer
2022-002426-28Phase 4Completed
- Sponsor
- Erasmus MC Cancer Institute
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tamoxifen in breast cancer, sponsored by Erasmus MC Cancer Institute. Primary endpoint: Proportion of patients achieving target endoxifen level at 3 months. Started Aug 2022; status: completed.
02
Drugs
tamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2022-002426-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002426-28.